VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Friday. The firm set a “sell” rating on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $2.50 target price on shares of VolitionRx in a report on Thursday, May 16th.

VolitionRx Stock Up 4.7 %

NYSE:VNRX opened at $0.60 on Friday. The company has a market cap of $49.51 million, a P/E ratio of -1.30 and a beta of 1.13. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.38. The business has a 50 day moving average price of $0.64 and a two-hundred day moving average price of $0.78.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.